Sareum Holdings PLC’s (LON:SAR) chief executive, Dr Tim Mitchell, will outline the potential of the company’s latest drug to fight a number of cancers when he attends a US conference later this month.
In lab models, SDC-1802, a TYK2/JAK1 inhibitor, significantly reduced tumour growth in cancers of the pancreas, colon, skin and kidney, plus B-cell lymphoma.
Saruem believes it may have developed a “potentially powerful” immunotherapy that will help combat the killer diseases.
Mitchell will give a poster presentation to the American Association for Cancer Research on October 29 outlining the latest findings. The poster is now available on the AACR website [click here].
"We are looking forward to presenting the data showing how our TYK2/JAK1 inhibitor, SDC-1802, induces a significant reduction of tumour growth in preclinical models of many cancer types via a novel immunotherapeutic mechanism of action,” said Mitchell.
“These data suggest that our TYK2/JAK1 inhibitor could also offer the additional potential advantage of oral delivery.
“This contrasts with currently marketed cancer immunotherapies, which can only be dosed by injection.
“We are delighted to be presenting at this important international cancer conference and engaging with interested parties from the many leading pharma and biotech companies that attend this event."